IL6R and arthritic joint disease: Tocilizumab can block the IL-6–IL-6R pathway by binding to IL-6R and has been approved to treat different types of arthritis. A phase II trial (NCT03004703) showed its ability to reduce hsCRP in the patients with NSTEMI. It also improved myocardial salvage index and facilitated hsCRP reduction in the patients with STEMI.